BRCA2 and melanoma: In support of the hypothesis that the genomic instability of HR-d tumors results in increased immunogenicity, a retrospective study of melanoma patients treated with ICI therapy found that tumors that regressed were enriched for BRCA2 loss of function mutations and harbored a higher TMB (37).